Effect of ranibizumab on serous pigment epithelial detachments associated with wet age-related macular degeneration_Chinese Journal of Ocular Fundus Diseases

Authors：

ZhaoChun , WangFang , ChenLei , 施岳辉 , 叶盛 , 徐璨卿 , 谢春蕾 ,  徐鼎

Tenth People's Hospital of Tongji University, Shanghai 200072, China;

Corresponding author：

徐鼎, Email: daisyxu70@hotmail.com

Keywords：

Choroidal neovascularization/drug therapy; Macular degeneration/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies; monoclonal/therapeutic use

DOI：

10.3760/cma.j.issn.1005-1015.2015.01.008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the effects of intravitreal ranibizumab therapy for serous pigment epithelial detachment (sPED) secondary to exudative age-related macular degeneration(eAMD). Methods Twenty-three eyes from 23 patients of eAMD with sPED were enrolled in this study. The best corrected visual acuity, ocular coherence tomography (OCT), maximum PED height from baseline, volume of PED and central fovea thickness(CFT)were collected monthly for these patients. And the patients were receiced intravitreal injection with ranibizumab of 0.5 mg of three consecutive monthly injections. Results No complications were observed during the study period. After 6 months follow-up, 17 eyes improved, 4 eyes unchanged and only 2 eye decreased. The best corrected visual acuity was from 0.77±0.39 up to 0.61±0.27(t=2.601, P < 0.05). It was observed by OCT that the PED height was decreased from (357.2±171.9)μm (before treatment) to (247.7±171.7)μm (after treatment) (t=3.192, P < 0.05) and the volume of PED was decreased from(0.741±1.012) mm³ to (0.337±0.498) mm³ (t=2.502, P < 0.05). The central foveal thickness was decreased from (317.9±73.8)μm to (302.5±89.3)μm, but the difference were no statistically significantly (t=0.887, P > 0.05). Conclusion Ranibizumab may be an effective treatment for improving vision and reducing the degree of PED in eAMD patients.

Citation： ZhaoChun, WangFang, ChenLei. Effect of ranibizumab on serous pigment epithelial detachments associated with wet age-related macular degeneration. Chinese Journal of Ocular Fundus Diseases, 2015, 31(1): 27-30. doi: 10.3760/cma.j.issn.1005-1015.2015.01.008 Copy

1.	Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age-related macular degeneration:classification and therapeutic options[J]. Semin Ophthalmol, 2011, 26(3):198-208.
2.	Baumal CR, Reichel E, Duker JS, et al. Indocyanine green hyperfluorescence associated with serous retinal pigment epithelial detachment in age-related macular degeneration[J]. Ophthalmology, 1997, 104(5):761-769.
3.	Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration[J]. N En J Med, 2006, 355(14):1419-1431.
4.	Panos GD, Gatzioufas Z, Petropoulos IK, et al. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration[J]. Drug Des Devel Ther, 2013, 7:565-569.
5.	孙晓东, 宋正宇, 王枫桦.抗血管内皮生长因子A药物治疗年龄相关性黄斑变性随访及再治疗的策略[J].中华实验眼科杂志, 2012, 30(5):385-387.
6.	Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age related macular degeneration:PIER Study year 1[J]. Am J Ophthalmol, 2008, 145(2):239-248.
7.	Chang TS, Bressler NM, Fine Jr, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration:results of a randomized clinical trial[J]. Arch Ophthalmol, 2007, 125(11):1460-1469.
8.	Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration:subgroup analysis of first-year ANCHOR results[J]. Am J Ophthalmol, 2007, 144(6):850-857.
9.	Menke MN, Zinkernagel MS, Ebneter A, et al. Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen[J]. Br J Ophthalmol, 2014, 98(9):1197-2000.
10.	Schmidt EU, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration:the EXCITE study[J]. Ophthalmology, 2011, 118(5):831-839.
11.	Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab:phaseⅢclinical trial results[J]. Ophthalmol Clin North Am, 2006, 19(3):361-372.

1. Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age-related macular degeneration:classification and therapeutic options[J]. Semin Ophthalmol, 2011, 26(3):198-208.
2. Baumal CR, Reichel E, Duker JS, et al. Indocyanine green hyperfluorescence associated with serous retinal pigment epithelial detachment in age-related macular degeneration[J]. Ophthalmology, 1997, 104(5):761-769.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration[J]. N En J Med, 2006, 355(14):1419-1431.
4. Panos GD, Gatzioufas Z, Petropoulos IK, et al. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration[J]. Drug Des Devel Ther, 2013, 7:565-569.
5. 孙晓东, 宋正宇, 王枫桦.抗血管内皮生长因子A药物治疗年龄相关性黄斑变性随访及再治疗的策略[J].中华实验眼科杂志, 2012, 30(5):385-387.
6. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age related macular degeneration:PIER Study year 1[J]. Am J Ophthalmol, 2008, 145(2):239-248.
7. Chang TS, Bressler NM, Fine Jr, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration:results of a randomized clinical trial[J]. Arch Ophthalmol, 2007, 125(11):1460-1469.
8. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration:subgroup analysis of first-year ANCHOR results[J]. Am J Ophthalmol, 2007, 144(6):850-857.
9. Menke MN, Zinkernagel MS, Ebneter A, et al. Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen[J]. Br J Ophthalmol, 2014, 98(9):1197-2000.
10. Schmidt EU, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration:the EXCITE study[J]. Ophthalmology, 2011, 118(5):831-839.
11. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab:phaseⅢclinical trial results[J]. Ophthalmol Clin North Am, 2006, 19(3):361-372.

Chinese Journal of Ocular Fundus Diseases

Effect of ranibizumab on serous pigment epithelial detachments associated with wet age-related macular degeneration

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content